Novel ApoA-I/HDL raising drug, RVX-208, to be featured in oral
TSX Exchange Symbol: RVX
CALGARY, Oct. 11 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is
pleased to announce that tomorrow it is making an oral presentation
highlighting key scientific data of its lead clinical molecule, RVX-208, at
the International Atherosclerosis Society (IAS) Workshop on HDL. The
presentation titled "A novel drug that raises apolipoprotein A-I and HDL in
vitro and in vivo" will be presented by Dr. Norman Wong, Resverlogix
Co-Founder and Chairman of the Scientific Advisory Board on October 12th at
the Petros M. Nomikos Conference Center in Santorini, Greece.
"This meeting of the IAS attracts internationally elite scientists in
cardiovascular medicine. This venue is ideal for announcing the favorable and
novel features of RVX-208, scheduled for clinical trials later this year,"
stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs
of Resverlogix. Dr. Johansson added, "RVX-208 is a small molecule for oral
administration that has shown to have unprecedented effects in raising ApoA-I
and functional HDL. There is an ever-increasing body of evidence from
predictive animal models that indicates RVX-208's potential for preventing and
regressing atherosclerosis. We are very happy to participate in this important
Mr. Donald McCaffrey, President and CEO of Resverlogix said, "These
highly regarded researchers who will be participating at the event clearly
understand that there is a large unmet medical need in cardiovascular disease
(CVD). There is a lot of excitement among these key opinion leaders that
Resverlogix's novel small molecule drug could address many of the shortcomings
of current CVD drugs."
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements
are subject to a number of risks, uncertainties and assumptions. Actual
results and events may vary significantly. The TSX Exchange does not
accept responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com; Website: www.resverlogix.com